Senior management changes at Biodel
This article was originally published in Scrip
Executive Summary
The US speciality pharmaceutical company Biodel has named Dr Errol De Souza president and chief executive officer and Dr Charles Sanders board chairman. Dr Solomon Steiner, who co-founded Biodel in 2003, will become chief scientific officer and will remain a member of the board. Dr Sanders is the former chairman and CEO of Glaxo and was appointed to Biodel’s board in 2006. Dr De Souza has previously served as president and CEO of Synaptic Pharmaceuticals, president and CEO of Archemix, co-founder and chief scientific officer of Neurocrine Biosciences, senior vice-president and US site head of drug innovation and approval at Aventis and director of CNS diseases research at DuPont Merck. With the appointment of a non-executive board chairman, Biodel has eliminated the role of lead director, which had been held by director Scott Weisman.